Establishing Potosi Virus as a Human Pathogen - Part 1
From Neurology® Podcast · · 19 min
This plays from the publisher's own server. We do not host a copy.
Description
In part one of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about why infection can be overlooked in people on anti-CD20 therapy and practical ways clinicians can improve testing, prevention, vaccination, and collaboration with laboratories and infectious disease specialists.
Read the related article in Neurology®.
Disclosures can be found at Neurology.org (https://www.neurology.org/).
_______________________________________________
Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week.
Dr. Stacey Clardy: This is Stacey Clardy from the Salt Lake City VA and the University of Utah with a two-part neurology podcast. Today, we're talking about infections, specifically in people receiving anti-CD20 therapies, but also good food for thought and folks who are otherwise walking around immunosuppressed. And there's a case that inspired this podcast. So joining me to talk about that is Justin Abbatemarco from the Cleveland Clinic. You know him well as one of the voices of the podcast. He's also an autoimmune neurologist and he's the author on this report. The title of the report is Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient. Justin, thanks for agreeing to be interviewed today instead of leading the interview.
Dr. Justin Abbatemarco: It's much less comfortable on this side of the mic, Stacey.
Dr. Stacey Clardy: Yes. Yes, it is. But hey, we're all friends, so we'll just chat. So Justin, your report establishes that Potosi virus, which I have never heard of, can cause fatal encephalitis in humans. So what is this virus and what do I need to know about it? And what is this case teaching us, especially with our increased usage of all these B-cell depleting agents?
Dr. Justin Abbatemarco: This was a really humbling case that we had in service, and I think we have much more to learn about Potosi virus and its interaction with humans and immunocompromised hosts. This is only the second report and the only one with pathology to help confirm it. But the virus has been known for a really long time. It's been documented mosquito populations before this, but it's only been over these last few years that it's been linked with metagenomic next gen sequencing as a potential human pathogen. And so more to come. We really hope this report will spur further investigations on this, have this included as a human pathogen on metagenomic next gen sequencing reports. But I think the bigger thought process around here, it made us really think about it at our clinic on how we approach patients on CD20 medications or their immunosuppressive medications. Because the way this case presented initially, it really threw us. Infection was not on the top of our differential. And so some of the learning points about the traditional risk factors and how we think about testing, those are some major takeaways we had when we look back at this.
Dr. Stacey Clardy: So tell me about this. What did you think was going on? I read that her MS seemed to be fairly well controlled on a B-cell depleting agent. So how did she present so that it can scare me even more that I'm missing this?
Dr. Justin Abbatemarco: I know, it's so humbling. But she was 37, she was diagnosed with MS over a decade ago. She had been on some of our platform medications and in 2020 started rituximab and did incredibly well. Minimal disability on examination. IgG levels were normal. She actually worked in our hospital and by about four years on therapy, she starts developing some subtle symptoms, feels like she's having a hard time with attention processing, things we hear about all the time in clinic.
Dr. Stacey Clardy: Yeah.
Dr. Justin Abbatemarco: Everything looks stable from an MRI…